Clinical Trial Update: Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity, safety, and reactogenicity of Boostrix booster in healthy Russian adults completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria-Tetanus-acellular Pertussis Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2019-10-23